Docetaxel, Capecitabine, and Cisplatin in Treating Patients With Advanced Solid Tumors

DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed solid tumor for which standard curative or palliative measures do not exist or are no longer effective * Metastatic or unresectable disease * No known brain metastases PATIENT CHARACTERISTICS: Age * 18 and over Performance status * ECOG 0-2 Life expectancy * More than 12 weeks Hematopoietic * Absolute neutrophil count ≥ 1,500/mm\^3 * Platelet count ≥ 100,000/mm\^3 * Hemoglobin ≥ 8.0 g/dL Hepatic * AST and ALT ≤ 2.0 times upper limit of normal (ULN) AND alkaline phosphatase \[AP\] \< ULN OR * AP ≤ 4 times ULN AND AST and ALT \< ULN * Bilirubin normal Renal * Creatinine ≤ 1.5 mg/dL OR * Creatinine clearance ≥ 60 mL/min Cardiovascular * No symptomatic congestive heart failure * No unstable angina pectoris * No cardiac arrhythmia Other * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * Able to ingest oral medications * No allergy attributed to study drugs, compounds of similar chemical or biological composition, drugs formulated in polysorbate 80, or other agents used in this study * No inner ear auditory toxicity ≥ grade 2 * No peripheral neuropathy ≥ grade 2 * No immunodeficiency * No active or ongoing infection * No psychiatric illness or social situation that would preclude study compliance * No other concurrent uncontrolled illness PRIOR CONCURRENT THERAPY: Biologic therapy * No concurrent growth factors (sargramostim \[GM-CSF\] or filgrastim \[G-CSF\]) Chemotherapy * More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered Endocrine therapy * Not specified Radiotherapy * More than 4 weeks since prior radiotherapy and recovered Surgery * Not specified Other * No other concurrent investigational agents unless approved by the principal investigator and medical monitor * No other concurrent anticancer therapy